Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (6713)	2/8/2001 10:27:44 PM
From: Joe Krupa	Respond to of 14101

IMO, a very key quote from that article, Wolf: "Based on the findings, the FDA is unlikely to allow either Vioxx or Celebrex to make general claims of greater safety than NSAIDs, but merely respective advantages over different individual NSAIDs, he said."

To: Montana Wildhack who wrote (6713)	2/9/2001 9:10:22 AM
From: Cal Gary	Respond to of 14101

Hi Wolf With the recent FDA decision around Celebrex/Vioxx, are you raising your 5% market share for Pennsaid? And to what %?? Thanks muchly. I recall several conversations I had the past year with GPs and a heart specialist. They adopted Celebrex/Vioxx very quickly for their practices because of the then safety profile. The heart specialist did mention he was concerned about link to heart attacks (? not 100% if that was his words) many moons ago. Celebrex/Vioxx Safe, but not that Safe Pennsaid Safe, Very Safe (I always wanted to say that <ggg>)